In vitro studies have proven that MitoQ protects neuronal models of Parkinson’s disease (PD) against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced behavioral deficit, tyrosine hydroxylase (TH)-positive neuronal loss, depletion of striatal dopamine, inactivation of mitochondrial aconitase, neuronal apoptosis and cell death [81]. This evidence concerns the gene TH and Parkinson disease.